Saturday, February 09, 2019 11:13:28 AM
Zacks had it wrong on H&N cancer survival. They can't have it all right, right ?
Geert initially indicated "early 2019"
We managed to get survival figure from feb 2017 and feb 2018 which indicated 133 and 208 events. This alone sets an earliest possible date for April 2019. More sophisticated models provide October. Strong uncertainty do persist on the date but it won't be february. It could be earlier (july, august,...). You're a CPA, you can do the math yourself
After we got this finding from a member of the MB, we communicated on it and its consequences, the link, from a Taïwanese hospital was... broken
Geert didn't calculate right and voluntarily concealed those figures for specific reasons.
I can guess some reasons, I'll let you provide others if you want:
- October 2019 would mean refunding (dilution) coming while earlier date would allow earlier speculation. We now have heard about those pending warrants.
- Geert personnal revenge against those who put obstacle through his way. He knows he is certain on of success. He can play with the investing community
-May be this means bad news, but I can't see how
Fosco
Recent CVM News
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
